

November 8, 2018



Khiron Life Sciences Welcomes Cannabis Legislation Proposed by Incoming Government of Mexico

TORONTO, Nov. 8, 2018 /CNW/ - Khiron Life Sciences Corp. (**Khiron**" or the "**Company**") (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), an integrated medical cannabis company with its core operations in Colombia, welcomes the initiative presented yesterday by the incoming Government of Mexico through its next secretary of the Interior, Dr. Olga Sánchez Cordero, for the Regulation and Control of Cannabis in Mexico.

The General Law for the Regulation and Control of Cannabis, presented by Dr. Olga Sanchez will establish Mexico among Latin American countries that have legislated the use of cannabis for recreational, medical, scientific, research, industrial and commercial purposes. Mexico has the second largest population in Latin America and 11.7 million potential patients for medical cannabis. (*source: IMS Quintiles 2017*). The new legislation will develop in more detail the conditions for recreational cannabis use already authorized by judicial decisions, and also define final details for medical use.

Alvaro Torres, Co-founder and CEO for Khiron stated, "Khiron is a leader in the medical cannabis sector in Latin America working with all levels of government, health professionals and patients to establish a safe and regulated cannabis environment. We welcome the presentation made yesterday by the next secretary of Interior, Dr. Olga Sánchez Cordero, and we look forward to the opportunity to work with the administration to develop a strong and successful cannabis industry in Mexico."

Former Mexican President and Khiron board member Mr. Vicente Fox stated, "As a Latin America focused company, Khiron is positioned to maximize the legislation proposed yesterday and to bring the benefits of a legalized cannabis environment to all Mexicans, which has the potential to reduce crime, increase prosperity and improve the health of our citizens."

About Khiron Life Sciences Corp.

Khiron Life Sciences Corp. (TSXV: KHRN, OTCQB: KHRNF, Frankfurt: A2JMZC) ("Khiron" or the "Company") is positioned to be the dominant integrated medical cannabis company in Latin America. Khiron has core operations in Colombia and is fully licensed in the country for the cultivation, production, domestic distribution, and international export of both tetrahydrocannabinol (THC) and cannabidiol (CBD) medical cannabis. In May 2018, Khiron listed on the TSX Venture Exchange, becoming one of the first Colombian based medical cannabis companies to trade on any exchange globally.

With a focused regional strategy and patient oriented approach, the Company combines global scientific expertise, agricultural advantages, branded product market entrance

experience and education to drive prescription and brand loyalty to address priority medical conditions such as chronic pain, epilepsy, depression and anxiety in the Latin American market of over 620 million people. Khiron is led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced executive team, and a knowledgeable Board of Directors that includes former President of Mexico, Vicente Fox.

Further information on Khiron Life Sciences can be found at www.khiron.ca.

Forward-Looking Statements

This press release may contain certain forward-looking information and statements ("forward-looking information") within the meaning of applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. Readers are cautioned to not place undue reliance on forward-looking information. Actual results and developments may differ materially from those contemplated by these statements. Khiron undertakes no obligation to comment analyses, expectations or statements made by third-parties in respect of Khiron, its securities, or financial or operating results (as applicable). Although Khiron believes that the expectations reflected in forward-looking information in this press release are reasonable, such forward-looking information has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond Khiron's control, including the risk factors discussed in Khiron's Filing Statement which is available on Khiron's SEDAR profile at www.sedar.com. The forward-looking information contained in this press release is expressly qualified by this cautionary statement and are made as of the date hereof. Khiron disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.

SOURCE Khiron Life Sciences Corp.

For further information: Investor Contacts: Chris Naprawa, President, T: +1 (416) 705-1144, E: cnaprawa@khiron.ca; Darren Collins, Chief Financial Officer, T: +1 (705) 527-3564, E: dcollins@khiron.ca; Media Contact: Jon Packer, Vice President, Communications, T: +1 (416) 543-9179, E: jpacker@khiron.ca